Journal
ALZHEIMERS & DEMENTIA
Volume 11, Issue 2, Pages 226-235Publisher
ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2014.02.005
Keywords
Alzheimer's disease; Brain atrophy; Cognition; Docosahexaenoic acid; Omega-3
Categories
Funding
- Alzheimer's Disease Neuroimaging Initiative (National Institutes of Health) [U01 AG024904]
- National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering
- Abbott
- Alzheimer's Drug Discovery Foundation
- Amorfix Life Sciences Ltd
- AstraZeneca
- Bayer HealthCare
- BioClinica, Inc
- Biogen Idec, Inc
- Bristol-Myers Squibb Company
- Eisai Inc
- Elan Pharmaceuticals, Inc
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd, company Genentech, Inc
- GE Healthcare
- Innogenetics, N.V.
- IXICO Ltd
- Janssen Alzheimer Immunotherapy Research AMP
- Development, LLC
- Johnson AMP
- Johnson Pharmaceutical Research AMP
- Development LLC
- Medpace, Inc
- Merck Co, Inc
- Meso Scale Diagnostics, LLC
- Novartis Pharmaceuticals Corporation
- Pfizer Inc
- Servier
- Synarc Inc
- Takeda Pharmaceutical Company
- Canadian Institutes of Health Research
- NIH [P30 AG010129, K01 AG030514]
- Alzheimer's Association
Ask authors/readers for more resources
Objective: The aim of this study was to investigate whether the use of fish oil supplements (FOSs) is associated with concomitant reduction in cognitive decline and brain atrophy in older adults. Methods: We conducted a retrospective cohort study to examine the relationship between FOS use during the Alzheimer's Disease Neuroimaging Initiative and indicators of cognitive decline. Older adults (229 cognitively normal individuals, 397 patients with mild cognitive impairment, and 193 patients with Alzheimer's disease) were assessed with neuropsychological tests and brain magnetic resonance imaging every 6 months. Primary outcomes included (1) global cognitive status and (2) cerebral cortex gray matter and hippocampus and ventricular volumes. Results: FOS use during follow-up was associated with significantly lower mean cognitive subscale of the Alzheimer's Disease Assessment Scale and higher Mini-Mental State Examination scores among those with normal cognition. Associations between FOS use and the outcomes were observed only in APOE epsilon 4 negative participants. FOS use during the study was also associated with less atrophy in one or more brain regions of interest. (C) 2015 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available